BeyondSpring (BYSI) Income towards Parent Company (2016 - 2026)
BeyondSpring (BYSI) posted Income towards Parent Company of -$4.3 million for Q1 2026, down 31.64% sequentially from -$3.3 million in Q4 2025, and down 161.88% YoY from $7.0 million in Q1 2025.
BeyondSpring (BYSI) Income towards Parent Company (2016 - 2026) Analysis & Trends
BeyondSpring has reported Income towards Parent Company for 9 years, with the latest figure at -$4.3 million in Q1 2026.
- Quarterly Income towards Parent Company fell 161.88% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.2 million (down 325.87% YoY) and the FY2025 annual result came in at -$12.5 million, down 59.53% from the prior year.
- Income towards Parent Company declined to -$4.3 million in Q1 2026 per BYSI's latest filing, from -$3.3 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $7.0 million in Q1 2025 and troughed at -$12.8 million in Q3 2025.
- A 3-year average of -$3.3 million and a median of -$2.8 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2025 and 2026: Income towards Parent Company surged 678.31% in 2025, then slumped 161.88% in 2026.
- Over 3 years, Income towards Parent Company stood at -$2.8 million in 2024, then dropped by 16.29% to -$3.3 million in 2025, then slumped by 31.64% to -$4.3 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$4.3 million, -$3.3 million, and -$12.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.95 Mn |
| Mar 31, 2026 | -4.32 Mn |
| Dec 31, 2025 | -3.28 Mn |
| Sep 30, 2025 | -12.78 Mn |
| Jun 30, 2025 | -2.77 Mn |
| Mar 31, 2025 | 6.99 Mn |
| Dec 31, 2024 | -2.82 Mn |
| Sep 30, 2024 | -8.16 Mn |
| Jun 30, 2024 | -1.44 Mn |
| Mar 31, 2024 | -1.21 Mn |
| Dec 31, 2021 | 6.42 Mn |
| Sep 30, 2021 | -20.14 Mn |
| Jun 30, 2021 | -19.89 Mn |
| Mar 31, 2021 | -17.44 Mn |
| Dec 31, 2020 | -4.97 Mn |
| Sep 30, 2020 | -15.18 Mn |
| Jun 30, 2020 | -13.60 Mn |
| Mar 31, 2020 | -16.66 Mn |
| Dec 31, 2019 | -6.59 Mn |
| Sep 30, 2019 | -9.82 Mn |